Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RTI’s Silver Lining: Sterling Bone Void Approval Sends Stock Up 21% In August

This article was originally published in The Gray Sheet

Executive Summary

Regeneration Technologies' receipt of FDA clearance for the Sterling xenograft bone void fillers helped push the firm's stock price up 21% to $9.25 in August

You may also be interested in...



Tissue Product Distributors Disappoint RTI, May Prompt Sales Autonomy

Regeneration Technologies, Inc. (RTI) will consider creating an independent sales force after Medtronic placed fewer orders during Q1, causing RTI spinal revenue to drop by nearly half

Cardiac Science’s Quinton Merger Bolsters Balance Sheet, Competitiveness

Cardiac Science's merger with Quinton Cardiology Systems will eliminate debt to facilitate competition in the public-access defibrillator market, the firm says

COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers

First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel